grant

I4C 2.0: Immunotherapy for Cure

Organization BETH ISRAEL DEACONESS MEDICAL CENTERLocation BOSTON, UNITED STATESPosted 16 Aug 2021Deadline 30 Apr 2027
NIHUS FederalResearch GrantFY2025AcademiaActive ImmunizationActive vaccinationAgonistB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBindingCAR T cellsCAR modified T cellsCAR-TCAR-TsClonal ExpansionCommunitiesCommunity NetworksCytotoxic cellDisease remissionEngineeringEnsureFeedbackFinancial SupportGoalsGovernmentHIV-1HIV-IHIV1HumanHuman Immunodeficiency Virus Type 1Human immunodeficiency virus 1ImmuneImmune SurveillanceImmune mediated therapyImmune responseImmunesImmunochemical ImmunologicImmunologicImmunologic SurveillanceImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunosurveillanceImmunotherapyIndustryK lymphocyteLogisticsM mulattaM. mulattaMacaca mulattaMacaca rhesusModern ManMolecular InteractionMonkeysNK CellsNational Institutes of HealthNatural Killer CellsPassive ImmunizationRegimenRemissionResearchResearch ResourcesResidualResidual stateResourcesRhesus MacaqueRhesus MonkeySHIVSIVSamplingSimian Immunodeficiency VirusesT cells for CART-CellsT-LymphocyteTLR7TLR7 geneToll-Like Receptor 7United States National Institutes of HealthVAC-TXVaccine TherapyViralViral reservoirVirusVirus reservoirchallenge in rhesus macaqueschimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical developmentcommunity engagementengagement with communitiesengineered immune systemfinancial assistancehost responseimmune engineeringimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoengineeringimmunoresponseimprovedinfected rhesus macaquesinfected rhesus monkeyinfection in rhesus macaquesinfection of rhesus macaquesinnovateinnovationinnovativeneutralizing antibodynew approachesnovel approachesnovel strategiesnovel strategyoperationoperationspassive vaccinationpreventpreventingprogramsrhesus challengerhesus macaque challengerhesus monkey infectionsimian HIVsimian human immunodeficiency virustherapeutic vaccinationtherapeutic vaccinethymus derived lymphocytetimelinetranscriptomicstreatment vaccinesvaccine for the treatmentvaccine for treatmentviral reboundvirus rebound
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

SUMMARY
The goals of I4C 2.0 are to advance our scientific understanding of the viral reservoir and to develop immunologic

strategies for HIV-1 remission and eradication by a highly collaborative and multifaceted research program

involving partnerships among academia, industry, government, and the community. Our overall hypothesis is

that multiple immunologic strategies will need to be explored and combined to achieve long-term, ART-

free virologic control or complete virus eradication, with the goal of selecting combination regimens to

advance into clinical development by the end of the proposed period of support. We propose three

Research Foci, a Management and Operations Section, and a Community Engagement Section.

Focus 1 (Mechanistic Basis of Reservoir Targeting and Viral Persistence)

Aim 1. To define a virologic, immunologic, and transcriptomic signature of viral persistence and rebound and to

determine how immunologic strategies target the viral reservoir in NHPs and humans

Aim 2. To define drivers of clonal expansion and persistence of the replication-competent viral reservoir in NHPs

and humans to enhance reservoir control and elimination

Focus 2 (Novel Strategies for Sustained Virus Remission)

Aim 1. To evaluate innovative immune engineering strategies that provide long-term T cell or Env-directed

immune control, including therapeutic vaccines, CAR-T cells, and engineered B cells

Aim 2. To combine approaches that augment humoral and cellular immune responses to achieve sustained

immunosurveillance and long-term ART-free virologic control

Focus 3 (Novel Strategies for Virus Eradication)

Aim 1. To evaluate innovative strategies for rapid elimination of the majority of the viral reservoir, including

improved LRAs combined with bNAbs, activated NK cells, and CAR-T cells

Aim 2. To combine the most effective approach to rapidly eliminate the majority of the viral reservoir with

sustained immunosurveillance to eliminate the residual viral reservoir

Management and Operations (MO) Section

Community Engagement (CE) Section

Grant Number: 5UM1AI164556-05
NIH Institute/Center: NIH

Principal Investigator: Dan Barouch

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →